Biomed Research International-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2097357, encodeId=b555209e357da, content=偏重的研究方向：NAFLD;EMF 经验分享：记录一下，2022年10月29日晚20:21完成线上投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ergGzxpIkMZRKFNYwbbKrp2gBkJlqQtHO50tXBbXRu4qeukAsq0qAbtA4dMIaXrb3Sm3gyJ4n4sPg/132, createdBy=0d641634889, createdName=bear2015, createdTime=Sat Oct 29 20:39:49 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898003, encodeId=b32589800389, content=返修后显示AE assigned ，一直是这个状态，多久可以接受呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e6c5389833, createdName=ms5000001292778018, createdTime=Mon Nov 09 16:34:35 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885413, encodeId=eb6b885413e5, content=投稿2个多月了，换了四个编辑，状态由之前的invited review，变成了status in process，第一次投这个杂志，请问战友门这是啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23672147014, createdName=不用写讨论的SCI, createdTime=Tue Sep 15 10:53:12 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892598, encodeId=c4bf89259816, content=请问返修之后状态是viewing an older version是什么意思？是编辑正在处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35055398663, createdName=ms8000000008569584, createdTime=Sat Oct 17 09:18:30 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924916, encodeId=c68292491675, content=请问各位大佬，Pending Approval是什么意思？在论坛看到有人说是返回了一部分审稿人的意见，也有人说是编辑已同意接收，等主编决定。盼有经验的大佬解释一下，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211121/f16d8113fd3d4f57b0fe8f9abeabc417/e07d776898ab4c8ea88532be0f7f84de.jpg, createdBy=205f1774607, createdName=ms9501205579844494, createdTime=Tue Feb 16 16:33:38 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915918, encodeId=8ba79159180c, content=大家有三个月还没有邀请到AE得吗？我这种情况是不是可以申请撤稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/26e36f5bb23946aba0a0b7285aa5d95a/1b407ddebf4b4b5a8f4dad5535364c5f.jpg, createdBy=cdce5080023, createdName=145af1d2m78暂无昵称, createdTime=Tue Jan 12 15:10:51 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881267, encodeId=4ce888126eb9, content=status in progress是啥意思？有没有投过的战友知道？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/01/1f9d0c2ab2b04bcb3272b90827c28e36.jpg, createdBy=025f2514435, createdName=李多多投文章, createdTime=Mon Aug 31 08:59:07 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924208, encodeId=34c192420802, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：替熟识的朋友写个评论非肿瘤无基础实验结合临床生信文章 2020-05-13 投稿 2020-05-21～2020-07-30 一直在更换编辑，后面因为一些私人原因没有关注了 2020-10-22 小修，只有一个审稿人意见，三四个意见，没有时间限制 2020-11-21 小修修回 2020-11-27 显示“revision request”，但是没有具体内容 2020-11-27 回复询问是何意思 2020-12-19 reviewers invited 2021-02-07 pending approval（猜测第二个审稿人直接给了accept） 2021-02-11 accepted 全程历时9个月，也不说多慢吧，就是眼瞅着版面费暴涨了！全程不下五次反复要求提供在医院就职的证明，就因为是第一次发sci，而且邮箱不是官方邮箱而是163邮箱，最终找医院证明盖章之后承认，真的烦的一批。。。最后祝各位新年快乐，发文顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Thu Feb 11 23:25:02 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997382, encodeId=0f1999e3821f, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:2400.0 偏重的研究方向：细胞因子 经验分享：从submit到接收，2个月不到： 2021-05-10 submit 2021-06-04 邀请到AE 2021-06-06 Pending approval 2021-06-19 小修 2021-06-23 小修修回 2021-07-05 pending approval 2021-07-06 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5692110322, createdName=1521f88033m, createdTime=Thu Jul 08 03:05:15 CST 2021, time=2021-07-08, status=1, ipAttribution=)]

2022-10-29 bear2015

偏重的研究方向：NAFLD;EMF
经验分享：记录一下，2022年10月29日晚20:21完成线上投稿。

45 24

展开24条回复

[GetPortalCommentsPageByObjectIdResponse(id=2097357, encodeId=b555209e357da, content=偏重的研究方向：NAFLD;EMF 经验分享：记录一下，2022年10月29日晚20:21完成线上投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ergGzxpIkMZRKFNYwbbKrp2gBkJlqQtHO50tXBbXRu4qeukAsq0qAbtA4dMIaXrb3Sm3gyJ4n4sPg/132, createdBy=0d641634889, createdName=bear2015, createdTime=Sat Oct 29 20:39:49 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898003, encodeId=b32589800389, content=返修后显示AE assigned ，一直是这个状态，多久可以接受呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e6c5389833, createdName=ms5000001292778018, createdTime=Mon Nov 09 16:34:35 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885413, encodeId=eb6b885413e5, content=投稿2个多月了，换了四个编辑，状态由之前的invited review，变成了status in process，第一次投这个杂志，请问战友门这是啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23672147014, createdName=不用写讨论的SCI, createdTime=Tue Sep 15 10:53:12 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892598, encodeId=c4bf89259816, content=请问返修之后状态是viewing an older version是什么意思？是编辑正在处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35055398663, createdName=ms8000000008569584, createdTime=Sat Oct 17 09:18:30 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924916, encodeId=c68292491675, content=请问各位大佬，Pending Approval是什么意思？在论坛看到有人说是返回了一部分审稿人的意见，也有人说是编辑已同意接收，等主编决定。盼有经验的大佬解释一下，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211121/f16d8113fd3d4f57b0fe8f9abeabc417/e07d776898ab4c8ea88532be0f7f84de.jpg, createdBy=205f1774607, createdName=ms9501205579844494, createdTime=Tue Feb 16 16:33:38 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915918, encodeId=8ba79159180c, content=大家有三个月还没有邀请到AE得吗？我这种情况是不是可以申请撤稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/26e36f5bb23946aba0a0b7285aa5d95a/1b407ddebf4b4b5a8f4dad5535364c5f.jpg, createdBy=cdce5080023, createdName=145af1d2m78暂无昵称, createdTime=Tue Jan 12 15:10:51 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881267, encodeId=4ce888126eb9, content=status in progress是啥意思？有没有投过的战友知道？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/01/1f9d0c2ab2b04bcb3272b90827c28e36.jpg, createdBy=025f2514435, createdName=李多多投文章, createdTime=Mon Aug 31 08:59:07 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924208, encodeId=34c192420802, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：替熟识的朋友写个评论非肿瘤无基础实验结合临床生信文章 2020-05-13 投稿 2020-05-21～2020-07-30 一直在更换编辑，后面因为一些私人原因没有关注了 2020-10-22 小修，只有一个审稿人意见，三四个意见，没有时间限制 2020-11-21 小修修回 2020-11-27 显示“revision request”，但是没有具体内容 2020-11-27 回复询问是何意思 2020-12-19 reviewers invited 2021-02-07 pending approval（猜测第二个审稿人直接给了accept） 2021-02-11 accepted 全程历时9个月，也不说多慢吧，就是眼瞅着版面费暴涨了！全程不下五次反复要求提供在医院就职的证明，就因为是第一次发sci，而且邮箱不是官方邮箱而是163邮箱，最终找医院证明盖章之后承认，真的烦的一批。。。最后祝各位新年快乐，发文顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Thu Feb 11 23:25:02 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997382, encodeId=0f1999e3821f, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:2400.0 偏重的研究方向：细胞因子 经验分享：从submit到接收，2个月不到： 2021-05-10 submit 2021-06-04 邀请到AE 2021-06-06 Pending approval 2021-06-19 小修 2021-06-23 小修修回 2021-07-05 pending approval 2021-07-06 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5692110322, createdName=1521f88033m, createdTime=Thu Jul 08 03:05:15 CST 2021, time=2021-07-08, status=1, ipAttribution=)]

2020-11-09 ms5000001292778018

返修后显示AE assigned ，一直是这个状态，多久可以接受呢？

151 17

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=2097357, encodeId=b555209e357da, content=偏重的研究方向：NAFLD;EMF 经验分享：记录一下，2022年10月29日晚20:21完成线上投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ergGzxpIkMZRKFNYwbbKrp2gBkJlqQtHO50tXBbXRu4qeukAsq0qAbtA4dMIaXrb3Sm3gyJ4n4sPg/132, createdBy=0d641634889, createdName=bear2015, createdTime=Sat Oct 29 20:39:49 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898003, encodeId=b32589800389, content=返修后显示AE assigned ，一直是这个状态，多久可以接受呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e6c5389833, createdName=ms5000001292778018, createdTime=Mon Nov 09 16:34:35 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885413, encodeId=eb6b885413e5, content=投稿2个多月了，换了四个编辑，状态由之前的invited review，变成了status in process，第一次投这个杂志，请问战友门这是啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23672147014, createdName=不用写讨论的SCI, createdTime=Tue Sep 15 10:53:12 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892598, encodeId=c4bf89259816, content=请问返修之后状态是viewing an older version是什么意思？是编辑正在处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35055398663, createdName=ms8000000008569584, createdTime=Sat Oct 17 09:18:30 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924916, encodeId=c68292491675, content=请问各位大佬，Pending Approval是什么意思？在论坛看到有人说是返回了一部分审稿人的意见，也有人说是编辑已同意接收，等主编决定。盼有经验的大佬解释一下，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211121/f16d8113fd3d4f57b0fe8f9abeabc417/e07d776898ab4c8ea88532be0f7f84de.jpg, createdBy=205f1774607, createdName=ms9501205579844494, createdTime=Tue Feb 16 16:33:38 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915918, encodeId=8ba79159180c, content=大家有三个月还没有邀请到AE得吗？我这种情况是不是可以申请撤稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/26e36f5bb23946aba0a0b7285aa5d95a/1b407ddebf4b4b5a8f4dad5535364c5f.jpg, createdBy=cdce5080023, createdName=145af1d2m78暂无昵称, createdTime=Tue Jan 12 15:10:51 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881267, encodeId=4ce888126eb9, content=status in progress是啥意思？有没有投过的战友知道？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/01/1f9d0c2ab2b04bcb3272b90827c28e36.jpg, createdBy=025f2514435, createdName=李多多投文章, createdTime=Mon Aug 31 08:59:07 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924208, encodeId=34c192420802, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：替熟识的朋友写个评论非肿瘤无基础实验结合临床生信文章 2020-05-13 投稿 2020-05-21～2020-07-30 一直在更换编辑，后面因为一些私人原因没有关注了 2020-10-22 小修，只有一个审稿人意见，三四个意见，没有时间限制 2020-11-21 小修修回 2020-11-27 显示“revision request”，但是没有具体内容 2020-11-27 回复询问是何意思 2020-12-19 reviewers invited 2021-02-07 pending approval（猜测第二个审稿人直接给了accept） 2021-02-11 accepted 全程历时9个月，也不说多慢吧，就是眼瞅着版面费暴涨了！全程不下五次反复要求提供在医院就职的证明，就因为是第一次发sci，而且邮箱不是官方邮箱而是163邮箱，最终找医院证明盖章之后承认，真的烦的一批。。。最后祝各位新年快乐，发文顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Thu Feb 11 23:25:02 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997382, encodeId=0f1999e3821f, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:2400.0 偏重的研究方向：细胞因子 经验分享：从submit到接收，2个月不到： 2021-05-10 submit 2021-06-04 邀请到AE 2021-06-06 Pending approval 2021-06-19 小修 2021-06-23 小修修回 2021-07-05 pending approval 2021-07-06 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5692110322, createdName=1521f88033m, createdTime=Thu Jul 08 03:05:15 CST 2021, time=2021-07-08, status=1, ipAttribution=)]

2020-09-15 不用写讨论的SCI

投稿2个多月了，换了四个编辑，状态由之前的invited review，变成了status in process，第一次投这个杂志，请问战友门这是啥意思啊

143 16

展开16条回复

[GetPortalCommentsPageByObjectIdResponse(id=2097357, encodeId=b555209e357da, content=偏重的研究方向：NAFLD;EMF 经验分享：记录一下，2022年10月29日晚20:21完成线上投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ergGzxpIkMZRKFNYwbbKrp2gBkJlqQtHO50tXBbXRu4qeukAsq0qAbtA4dMIaXrb3Sm3gyJ4n4sPg/132, createdBy=0d641634889, createdName=bear2015, createdTime=Sat Oct 29 20:39:49 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898003, encodeId=b32589800389, content=返修后显示AE assigned ，一直是这个状态，多久可以接受呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e6c5389833, createdName=ms5000001292778018, createdTime=Mon Nov 09 16:34:35 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885413, encodeId=eb6b885413e5, content=投稿2个多月了，换了四个编辑，状态由之前的invited review，变成了status in process，第一次投这个杂志，请问战友门这是啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23672147014, createdName=不用写讨论的SCI, createdTime=Tue Sep 15 10:53:12 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892598, encodeId=c4bf89259816, content=请问返修之后状态是viewing an older version是什么意思？是编辑正在处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35055398663, createdName=ms8000000008569584, createdTime=Sat Oct 17 09:18:30 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924916, encodeId=c68292491675, content=请问各位大佬，Pending Approval是什么意思？在论坛看到有人说是返回了一部分审稿人的意见，也有人说是编辑已同意接收，等主编决定。盼有经验的大佬解释一下，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211121/f16d8113fd3d4f57b0fe8f9abeabc417/e07d776898ab4c8ea88532be0f7f84de.jpg, createdBy=205f1774607, createdName=ms9501205579844494, createdTime=Tue Feb 16 16:33:38 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915918, encodeId=8ba79159180c, content=大家有三个月还没有邀请到AE得吗？我这种情况是不是可以申请撤稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/26e36f5bb23946aba0a0b7285aa5d95a/1b407ddebf4b4b5a8f4dad5535364c5f.jpg, createdBy=cdce5080023, createdName=145af1d2m78暂无昵称, createdTime=Tue Jan 12 15:10:51 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881267, encodeId=4ce888126eb9, content=status in progress是啥意思？有没有投过的战友知道？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/01/1f9d0c2ab2b04bcb3272b90827c28e36.jpg, createdBy=025f2514435, createdName=李多多投文章, createdTime=Mon Aug 31 08:59:07 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924208, encodeId=34c192420802, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：替熟识的朋友写个评论非肿瘤无基础实验结合临床生信文章 2020-05-13 投稿 2020-05-21～2020-07-30 一直在更换编辑，后面因为一些私人原因没有关注了 2020-10-22 小修，只有一个审稿人意见，三四个意见，没有时间限制 2020-11-21 小修修回 2020-11-27 显示“revision request”，但是没有具体内容 2020-11-27 回复询问是何意思 2020-12-19 reviewers invited 2021-02-07 pending approval（猜测第二个审稿人直接给了accept） 2021-02-11 accepted 全程历时9个月，也不说多慢吧，就是眼瞅着版面费暴涨了！全程不下五次反复要求提供在医院就职的证明，就因为是第一次发sci，而且邮箱不是官方邮箱而是163邮箱，最终找医院证明盖章之后承认，真的烦的一批。。。最后祝各位新年快乐，发文顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Thu Feb 11 23:25:02 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997382, encodeId=0f1999e3821f, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:2400.0 偏重的研究方向：细胞因子 经验分享：从submit到接收，2个月不到： 2021-05-10 submit 2021-06-04 邀请到AE 2021-06-06 Pending approval 2021-06-19 小修 2021-06-23 小修修回 2021-07-05 pending approval 2021-07-06 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5692110322, createdName=1521f88033m, createdTime=Thu Jul 08 03:05:15 CST 2021, time=2021-07-08, status=1, ipAttribution=)]

2020-10-17 ms8000000008569584

请问返修之后状态是viewing an older version是什么意思？是编辑正在处理吗？

178 15

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=2097357, encodeId=b555209e357da, content=偏重的研究方向：NAFLD;EMF 经验分享：记录一下，2022年10月29日晚20:21完成线上投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ergGzxpIkMZRKFNYwbbKrp2gBkJlqQtHO50tXBbXRu4qeukAsq0qAbtA4dMIaXrb3Sm3gyJ4n4sPg/132, createdBy=0d641634889, createdName=bear2015, createdTime=Sat Oct 29 20:39:49 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898003, encodeId=b32589800389, content=返修后显示AE assigned ，一直是这个状态，多久可以接受呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e6c5389833, createdName=ms5000001292778018, createdTime=Mon Nov 09 16:34:35 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885413, encodeId=eb6b885413e5, content=投稿2个多月了，换了四个编辑，状态由之前的invited review，变成了status in process，第一次投这个杂志，请问战友门这是啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23672147014, createdName=不用写讨论的SCI, createdTime=Tue Sep 15 10:53:12 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892598, encodeId=c4bf89259816, content=请问返修之后状态是viewing an older version是什么意思？是编辑正在处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35055398663, createdName=ms8000000008569584, createdTime=Sat Oct 17 09:18:30 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924916, encodeId=c68292491675, content=请问各位大佬，Pending Approval是什么意思？在论坛看到有人说是返回了一部分审稿人的意见，也有人说是编辑已同意接收，等主编决定。盼有经验的大佬解释一下，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211121/f16d8113fd3d4f57b0fe8f9abeabc417/e07d776898ab4c8ea88532be0f7f84de.jpg, createdBy=205f1774607, createdName=ms9501205579844494, createdTime=Tue Feb 16 16:33:38 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915918, encodeId=8ba79159180c, content=大家有三个月还没有邀请到AE得吗？我这种情况是不是可以申请撤稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/26e36f5bb23946aba0a0b7285aa5d95a/1b407ddebf4b4b5a8f4dad5535364c5f.jpg, createdBy=cdce5080023, createdName=145af1d2m78暂无昵称, createdTime=Tue Jan 12 15:10:51 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881267, encodeId=4ce888126eb9, content=status in progress是啥意思？有没有投过的战友知道？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/01/1f9d0c2ab2b04bcb3272b90827c28e36.jpg, createdBy=025f2514435, createdName=李多多投文章, createdTime=Mon Aug 31 08:59:07 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924208, encodeId=34c192420802, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：替熟识的朋友写个评论非肿瘤无基础实验结合临床生信文章 2020-05-13 投稿 2020-05-21～2020-07-30 一直在更换编辑，后面因为一些私人原因没有关注了 2020-10-22 小修，只有一个审稿人意见，三四个意见，没有时间限制 2020-11-21 小修修回 2020-11-27 显示“revision request”，但是没有具体内容 2020-11-27 回复询问是何意思 2020-12-19 reviewers invited 2021-02-07 pending approval（猜测第二个审稿人直接给了accept） 2021-02-11 accepted 全程历时9个月，也不说多慢吧，就是眼瞅着版面费暴涨了！全程不下五次反复要求提供在医院就职的证明，就因为是第一次发sci，而且邮箱不是官方邮箱而是163邮箱，最终找医院证明盖章之后承认，真的烦的一批。。。最后祝各位新年快乐，发文顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Thu Feb 11 23:25:02 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997382, encodeId=0f1999e3821f, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:2400.0 偏重的研究方向：细胞因子 经验分享：从submit到接收，2个月不到： 2021-05-10 submit 2021-06-04 邀请到AE 2021-06-06 Pending approval 2021-06-19 小修 2021-06-23 小修修回 2021-07-05 pending approval 2021-07-06 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5692110322, createdName=1521f88033m, createdTime=Thu Jul 08 03:05:15 CST 2021, time=2021-07-08, status=1, ipAttribution=)]

2021-02-16 ms9501205579844494

请问各位大佬，Pending Approval是什么意思？在论坛看到有人说是返回了一部分审稿人的意见，也有人说是编辑已同意接收，等主编决定。盼有经验的大佬解释一下，非常感谢！

193 15

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=2097357, encodeId=b555209e357da, content=偏重的研究方向：NAFLD;EMF 经验分享：记录一下，2022年10月29日晚20:21完成线上投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ergGzxpIkMZRKFNYwbbKrp2gBkJlqQtHO50tXBbXRu4qeukAsq0qAbtA4dMIaXrb3Sm3gyJ4n4sPg/132, createdBy=0d641634889, createdName=bear2015, createdTime=Sat Oct 29 20:39:49 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898003, encodeId=b32589800389, content=返修后显示AE assigned ，一直是这个状态，多久可以接受呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e6c5389833, createdName=ms5000001292778018, createdTime=Mon Nov 09 16:34:35 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885413, encodeId=eb6b885413e5, content=投稿2个多月了，换了四个编辑，状态由之前的invited review，变成了status in process，第一次投这个杂志，请问战友门这是啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23672147014, createdName=不用写讨论的SCI, createdTime=Tue Sep 15 10:53:12 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892598, encodeId=c4bf89259816, content=请问返修之后状态是viewing an older version是什么意思？是编辑正在处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35055398663, createdName=ms8000000008569584, createdTime=Sat Oct 17 09:18:30 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924916, encodeId=c68292491675, content=请问各位大佬，Pending Approval是什么意思？在论坛看到有人说是返回了一部分审稿人的意见，也有人说是编辑已同意接收，等主编决定。盼有经验的大佬解释一下，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211121/f16d8113fd3d4f57b0fe8f9abeabc417/e07d776898ab4c8ea88532be0f7f84de.jpg, createdBy=205f1774607, createdName=ms9501205579844494, createdTime=Tue Feb 16 16:33:38 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915918, encodeId=8ba79159180c, content=大家有三个月还没有邀请到AE得吗？我这种情况是不是可以申请撤稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/26e36f5bb23946aba0a0b7285aa5d95a/1b407ddebf4b4b5a8f4dad5535364c5f.jpg, createdBy=cdce5080023, createdName=145af1d2m78暂无昵称, createdTime=Tue Jan 12 15:10:51 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881267, encodeId=4ce888126eb9, content=status in progress是啥意思？有没有投过的战友知道？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/01/1f9d0c2ab2b04bcb3272b90827c28e36.jpg, createdBy=025f2514435, createdName=李多多投文章, createdTime=Mon Aug 31 08:59:07 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924208, encodeId=34c192420802, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：替熟识的朋友写个评论非肿瘤无基础实验结合临床生信文章 2020-05-13 投稿 2020-05-21～2020-07-30 一直在更换编辑，后面因为一些私人原因没有关注了 2020-10-22 小修，只有一个审稿人意见，三四个意见，没有时间限制 2020-11-21 小修修回 2020-11-27 显示“revision request”，但是没有具体内容 2020-11-27 回复询问是何意思 2020-12-19 reviewers invited 2021-02-07 pending approval（猜测第二个审稿人直接给了accept） 2021-02-11 accepted 全程历时9个月，也不说多慢吧，就是眼瞅着版面费暴涨了！全程不下五次反复要求提供在医院就职的证明，就因为是第一次发sci，而且邮箱不是官方邮箱而是163邮箱，最终找医院证明盖章之后承认，真的烦的一批。。。最后祝各位新年快乐，发文顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Thu Feb 11 23:25:02 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997382, encodeId=0f1999e3821f, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:2400.0 偏重的研究方向：细胞因子 经验分享：从submit到接收，2个月不到： 2021-05-10 submit 2021-06-04 邀请到AE 2021-06-06 Pending approval 2021-06-19 小修 2021-06-23 小修修回 2021-07-05 pending approval 2021-07-06 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5692110322, createdName=1521f88033m, createdTime=Thu Jul 08 03:05:15 CST 2021, time=2021-07-08, status=1, ipAttribution=)]

2022-04-27 ms4000001680289394

成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted

111 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=2097357, encodeId=b555209e357da, content=偏重的研究方向：NAFLD;EMF 经验分享：记录一下，2022年10月29日晚20:21完成线上投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ergGzxpIkMZRKFNYwbbKrp2gBkJlqQtHO50tXBbXRu4qeukAsq0qAbtA4dMIaXrb3Sm3gyJ4n4sPg/132, createdBy=0d641634889, createdName=bear2015, createdTime=Sat Oct 29 20:39:49 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898003, encodeId=b32589800389, content=返修后显示AE assigned ，一直是这个状态，多久可以接受呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e6c5389833, createdName=ms5000001292778018, createdTime=Mon Nov 09 16:34:35 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885413, encodeId=eb6b885413e5, content=投稿2个多月了，换了四个编辑，状态由之前的invited review，变成了status in process，第一次投这个杂志，请问战友门这是啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23672147014, createdName=不用写讨论的SCI, createdTime=Tue Sep 15 10:53:12 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892598, encodeId=c4bf89259816, content=请问返修之后状态是viewing an older version是什么意思？是编辑正在处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35055398663, createdName=ms8000000008569584, createdTime=Sat Oct 17 09:18:30 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924916, encodeId=c68292491675, content=请问各位大佬，Pending Approval是什么意思？在论坛看到有人说是返回了一部分审稿人的意见，也有人说是编辑已同意接收，等主编决定。盼有经验的大佬解释一下，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211121/f16d8113fd3d4f57b0fe8f9abeabc417/e07d776898ab4c8ea88532be0f7f84de.jpg, createdBy=205f1774607, createdName=ms9501205579844494, createdTime=Tue Feb 16 16:33:38 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915918, encodeId=8ba79159180c, content=大家有三个月还没有邀请到AE得吗？我这种情况是不是可以申请撤稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/26e36f5bb23946aba0a0b7285aa5d95a/1b407ddebf4b4b5a8f4dad5535364c5f.jpg, createdBy=cdce5080023, createdName=145af1d2m78暂无昵称, createdTime=Tue Jan 12 15:10:51 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881267, encodeId=4ce888126eb9, content=status in progress是啥意思？有没有投过的战友知道？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/01/1f9d0c2ab2b04bcb3272b90827c28e36.jpg, createdBy=025f2514435, createdName=李多多投文章, createdTime=Mon Aug 31 08:59:07 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924208, encodeId=34c192420802, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：替熟识的朋友写个评论非肿瘤无基础实验结合临床生信文章 2020-05-13 投稿 2020-05-21～2020-07-30 一直在更换编辑，后面因为一些私人原因没有关注了 2020-10-22 小修，只有一个审稿人意见，三四个意见，没有时间限制 2020-11-21 小修修回 2020-11-27 显示“revision request”，但是没有具体内容 2020-11-27 回复询问是何意思 2020-12-19 reviewers invited 2021-02-07 pending approval（猜测第二个审稿人直接给了accept） 2021-02-11 accepted 全程历时9个月，也不说多慢吧，就是眼瞅着版面费暴涨了！全程不下五次反复要求提供在医院就职的证明，就因为是第一次发sci，而且邮箱不是官方邮箱而是163邮箱，最终找医院证明盖章之后承认，真的烦的一批。。。最后祝各位新年快乐，发文顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Thu Feb 11 23:25:02 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997382, encodeId=0f1999e3821f, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:2400.0 偏重的研究方向：细胞因子 经验分享：从submit到接收，2个月不到： 2021-05-10 submit 2021-06-04 邀请到AE 2021-06-06 Pending approval 2021-06-19 小修 2021-06-23 小修修回 2021-07-05 pending approval 2021-07-06 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5692110322, createdName=1521f88033m, createdTime=Thu Jul 08 03:05:15 CST 2021, time=2021-07-08, status=1, ipAttribution=)]

2021-01-12 145af1d2m78暂无昵称

大家有三个月还没有邀请到AE得吗？我这种情况是不是可以申请撤稿了

229 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=2097357, encodeId=b555209e357da, content=偏重的研究方向：NAFLD;EMF 经验分享：记录一下，2022年10月29日晚20:21完成线上投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ergGzxpIkMZRKFNYwbbKrp2gBkJlqQtHO50tXBbXRu4qeukAsq0qAbtA4dMIaXrb3Sm3gyJ4n4sPg/132, createdBy=0d641634889, createdName=bear2015, createdTime=Sat Oct 29 20:39:49 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898003, encodeId=b32589800389, content=返修后显示AE assigned ，一直是这个状态，多久可以接受呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e6c5389833, createdName=ms5000001292778018, createdTime=Mon Nov 09 16:34:35 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885413, encodeId=eb6b885413e5, content=投稿2个多月了，换了四个编辑，状态由之前的invited review，变成了status in process，第一次投这个杂志，请问战友门这是啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23672147014, createdName=不用写讨论的SCI, createdTime=Tue Sep 15 10:53:12 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892598, encodeId=c4bf89259816, content=请问返修之后状态是viewing an older version是什么意思？是编辑正在处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35055398663, createdName=ms8000000008569584, createdTime=Sat Oct 17 09:18:30 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924916, encodeId=c68292491675, content=请问各位大佬，Pending Approval是什么意思？在论坛看到有人说是返回了一部分审稿人的意见，也有人说是编辑已同意接收，等主编决定。盼有经验的大佬解释一下，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211121/f16d8113fd3d4f57b0fe8f9abeabc417/e07d776898ab4c8ea88532be0f7f84de.jpg, createdBy=205f1774607, createdName=ms9501205579844494, createdTime=Tue Feb 16 16:33:38 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915918, encodeId=8ba79159180c, content=大家有三个月还没有邀请到AE得吗？我这种情况是不是可以申请撤稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/26e36f5bb23946aba0a0b7285aa5d95a/1b407ddebf4b4b5a8f4dad5535364c5f.jpg, createdBy=cdce5080023, createdName=145af1d2m78暂无昵称, createdTime=Tue Jan 12 15:10:51 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881267, encodeId=4ce888126eb9, content=status in progress是啥意思？有没有投过的战友知道？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/01/1f9d0c2ab2b04bcb3272b90827c28e36.jpg, createdBy=025f2514435, createdName=李多多投文章, createdTime=Mon Aug 31 08:59:07 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924208, encodeId=34c192420802, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：替熟识的朋友写个评论非肿瘤无基础实验结合临床生信文章 2020-05-13 投稿 2020-05-21～2020-07-30 一直在更换编辑，后面因为一些私人原因没有关注了 2020-10-22 小修，只有一个审稿人意见，三四个意见，没有时间限制 2020-11-21 小修修回 2020-11-27 显示“revision request”，但是没有具体内容 2020-11-27 回复询问是何意思 2020-12-19 reviewers invited 2021-02-07 pending approval（猜测第二个审稿人直接给了accept） 2021-02-11 accepted 全程历时9个月，也不说多慢吧，就是眼瞅着版面费暴涨了！全程不下五次反复要求提供在医院就职的证明，就因为是第一次发sci，而且邮箱不是官方邮箱而是163邮箱，最终找医院证明盖章之后承认，真的烦的一批。。。最后祝各位新年快乐，发文顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Thu Feb 11 23:25:02 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997382, encodeId=0f1999e3821f, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:2400.0 偏重的研究方向：细胞因子 经验分享：从submit到接收，2个月不到： 2021-05-10 submit 2021-06-04 邀请到AE 2021-06-06 Pending approval 2021-06-19 小修 2021-06-23 小修修回 2021-07-05 pending approval 2021-07-06 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5692110322, createdName=1521f88033m, createdTime=Thu Jul 08 03:05:15 CST 2021, time=2021-07-08, status=1, ipAttribution=)]

2020-08-31 李多多投文章

status in progress是啥意思？有没有投过的战友知道？

146 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=2097357, encodeId=b555209e357da, content=偏重的研究方向：NAFLD;EMF 经验分享：记录一下，2022年10月29日晚20:21完成线上投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ergGzxpIkMZRKFNYwbbKrp2gBkJlqQtHO50tXBbXRu4qeukAsq0qAbtA4dMIaXrb3Sm3gyJ4n4sPg/132, createdBy=0d641634889, createdName=bear2015, createdTime=Sat Oct 29 20:39:49 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898003, encodeId=b32589800389, content=返修后显示AE assigned ，一直是这个状态，多久可以接受呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e6c5389833, createdName=ms5000001292778018, createdTime=Mon Nov 09 16:34:35 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885413, encodeId=eb6b885413e5, content=投稿2个多月了，换了四个编辑，状态由之前的invited review，变成了status in process，第一次投这个杂志，请问战友门这是啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23672147014, createdName=不用写讨论的SCI, createdTime=Tue Sep 15 10:53:12 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892598, encodeId=c4bf89259816, content=请问返修之后状态是viewing an older version是什么意思？是编辑正在处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35055398663, createdName=ms8000000008569584, createdTime=Sat Oct 17 09:18:30 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924916, encodeId=c68292491675, content=请问各位大佬，Pending Approval是什么意思？在论坛看到有人说是返回了一部分审稿人的意见，也有人说是编辑已同意接收，等主编决定。盼有经验的大佬解释一下，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211121/f16d8113fd3d4f57b0fe8f9abeabc417/e07d776898ab4c8ea88532be0f7f84de.jpg, createdBy=205f1774607, createdName=ms9501205579844494, createdTime=Tue Feb 16 16:33:38 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915918, encodeId=8ba79159180c, content=大家有三个月还没有邀请到AE得吗？我这种情况是不是可以申请撤稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/26e36f5bb23946aba0a0b7285aa5d95a/1b407ddebf4b4b5a8f4dad5535364c5f.jpg, createdBy=cdce5080023, createdName=145af1d2m78暂无昵称, createdTime=Tue Jan 12 15:10:51 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881267, encodeId=4ce888126eb9, content=status in progress是啥意思？有没有投过的战友知道？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/01/1f9d0c2ab2b04bcb3272b90827c28e36.jpg, createdBy=025f2514435, createdName=李多多投文章, createdTime=Mon Aug 31 08:59:07 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924208, encodeId=34c192420802, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：替熟识的朋友写个评论非肿瘤无基础实验结合临床生信文章 2020-05-13 投稿 2020-05-21～2020-07-30 一直在更换编辑，后面因为一些私人原因没有关注了 2020-10-22 小修，只有一个审稿人意见，三四个意见，没有时间限制 2020-11-21 小修修回 2020-11-27 显示“revision request”，但是没有具体内容 2020-11-27 回复询问是何意思 2020-12-19 reviewers invited 2021-02-07 pending approval（猜测第二个审稿人直接给了accept） 2021-02-11 accepted 全程历时9个月，也不说多慢吧，就是眼瞅着版面费暴涨了！全程不下五次反复要求提供在医院就职的证明，就因为是第一次发sci，而且邮箱不是官方邮箱而是163邮箱，最终找医院证明盖章之后承认，真的烦的一批。。。最后祝各位新年快乐，发文顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Thu Feb 11 23:25:02 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997382, encodeId=0f1999e3821f, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:2400.0 偏重的研究方向：细胞因子 经验分享：从submit到接收，2个月不到： 2021-05-10 submit 2021-06-04 邀请到AE 2021-06-06 Pending approval 2021-06-19 小修 2021-06-23 小修修回 2021-07-05 pending approval 2021-07-06 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5692110322, createdName=1521f88033m, createdTime=Thu Jul 08 03:05:15 CST 2021, time=2021-07-08, status=1, ipAttribution=)]

2021-02-11 机智肝帝武运昌隆欧洲呆

审稿速度:6.0 | 投稿命中率:50.0
经验分享：替熟识的朋友写个评论非肿瘤无基础实验结合临床生信文章 2020-05-13 投稿 2020-05-21～2020-07-30 一直在更换编辑，后面因为一些私人原因没有关注了 2020-10-22 小修，只有一个审稿人意见，三四个意见，没有时间限制 2020-11-21 小修修回 2020-11-27 显示“revision request”，但是没有具体内容 2020-11-27 回复询问是何意思 2020-12-19 reviewers invited 2021-02-07 pending approval（猜测第二个审稿人直接给了accept） 2021-02-11 accepted 全程历时9个月，也不说多慢吧，就是眼瞅着版面费暴涨了！全程不下五次反复要求提供在医院就职的证明，就因为是第一次发sci，而且邮箱不是官方邮箱而是163邮箱，最终找医院证明盖章之后承认，真的烦的一批。。。最后祝各位新年快乐，发文顺利。

164 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2097357, encodeId=b555209e357da, content=偏重的研究方向：NAFLD;EMF 经验分享：记录一下，2022年10月29日晚20:21完成线上投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ergGzxpIkMZRKFNYwbbKrp2gBkJlqQtHO50tXBbXRu4qeukAsq0qAbtA4dMIaXrb3Sm3gyJ4n4sPg/132, createdBy=0d641634889, createdName=bear2015, createdTime=Sat Oct 29 20:39:49 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898003, encodeId=b32589800389, content=返修后显示AE assigned ，一直是这个状态，多久可以接受呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e6c5389833, createdName=ms5000001292778018, createdTime=Mon Nov 09 16:34:35 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885413, encodeId=eb6b885413e5, content=投稿2个多月了，换了四个编辑，状态由之前的invited review，变成了status in process，第一次投这个杂志，请问战友门这是啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23672147014, createdName=不用写讨论的SCI, createdTime=Tue Sep 15 10:53:12 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892598, encodeId=c4bf89259816, content=请问返修之后状态是viewing an older version是什么意思？是编辑正在处理吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35055398663, createdName=ms8000000008569584, createdTime=Sat Oct 17 09:18:30 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924916, encodeId=c68292491675, content=请问各位大佬，Pending Approval是什么意思？在论坛看到有人说是返回了一部分审稿人的意见，也有人说是编辑已同意接收，等主编决定。盼有经验的大佬解释一下，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211121/f16d8113fd3d4f57b0fe8f9abeabc417/e07d776898ab4c8ea88532be0f7f84de.jpg, createdBy=205f1774607, createdName=ms9501205579844494, createdTime=Tue Feb 16 16:33:38 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915918, encodeId=8ba79159180c, content=大家有三个月还没有邀请到AE得吗？我这种情况是不是可以申请撤稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/26e36f5bb23946aba0a0b7285aa5d95a/1b407ddebf4b4b5a8f4dad5535364c5f.jpg, createdBy=cdce5080023, createdName=145af1d2m78暂无昵称, createdTime=Tue Jan 12 15:10:51 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881267, encodeId=4ce888126eb9, content=status in progress是啥意思？有没有投过的战友知道？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/01/1f9d0c2ab2b04bcb3272b90827c28e36.jpg, createdBy=025f2514435, createdName=李多多投文章, createdTime=Mon Aug 31 08:59:07 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924208, encodeId=34c192420802, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：替熟识的朋友写个评论非肿瘤无基础实验结合临床生信文章 2020-05-13 投稿 2020-05-21～2020-07-30 一直在更换编辑，后面因为一些私人原因没有关注了 2020-10-22 小修，只有一个审稿人意见，三四个意见，没有时间限制 2020-11-21 小修修回 2020-11-27 显示“revision request”，但是没有具体内容 2020-11-27 回复询问是何意思 2020-12-19 reviewers invited 2021-02-07 pending approval（猜测第二个审稿人直接给了accept） 2021-02-11 accepted 全程历时9个月，也不说多慢吧，就是眼瞅着版面费暴涨了！全程不下五次反复要求提供在医院就职的证明，就因为是第一次发sci，而且邮箱不是官方邮箱而是163邮箱，最终找医院证明盖章之后承认，真的烦的一批。。。最后祝各位新年快乐，发文顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Thu Feb 11 23:25:02 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997382, encodeId=0f1999e3821f, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:2400.0 偏重的研究方向：细胞因子 经验分享：从submit到接收，2个月不到： 2021-05-10 submit 2021-06-04 邀请到AE 2021-06-06 Pending approval 2021-06-19 小修 2021-06-23 小修修回 2021-07-05 pending approval 2021-07-06 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5692110322, createdName=1521f88033m, createdTime=Thu Jul 08 03:05:15 CST 2021, time=2021-07-08, status=1, ipAttribution=)]

2021-07-08 1521f88033m

审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:2400.0
偏重的研究方向：细胞因子
经验分享：从submit到接收，2个月不到：
2021-05-10 submit
2021-06-04 邀请到AE
2021-06-06 Pending approval
2021-06-19 小修
2021-06-23 小修修回
2021-07-05 pending approval
2021-07-06 接收

142 12

展开12条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务